Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0816120120150010013
Korean Journal of Pediatric Gastroenterolology and Nutrition
2012 Volume.15 No. 1 p.13 ~ p.18
Biological Therapy for Inflammatory Bowel Disease in Children
Na So-Young

Shim Jung-Ok
Abstract
The pathogenesis of inflammatory bowel diseases is not very well understood; it is currently thought to be caused by the interaction between genetic factors, environmental factors, intestinal microbes, and immune factors. Biological agents such as anti-tumor necrosis factor (anti-TNF) are widely being used as therapeutic agents. Infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, has been demonstrated to have an effect in the induction and maintenance of remission in Crohn¡¯s disease in children. The effects of biological agents, typified by anti-TNFs, in inflammatory bowel disease in children; the recent concern on the administration of biological agents in combination with immunomodulators; and ¡¯Top-down¡¯ therapy are some of the topics covered in this review.
KEYWORD
Inflammatory bowel disease, Infliximab, Children
FullTexts / Linksout information
  
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø